FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers
Katia A. Mesquita(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Islam M. Miligy(University of Nottingham), Adel Alblihy(University of Nottingham), Rachel Doherty(University of Nottingham), Ian Hickson(Janssen (United States)), Natalie J. Tatum(Cancer Research UK), Anton Simeonov(National Institutes of Health), Ajit Jadhav(National Institutes of Health), David M. Wilson(Hasselt University), Dorjbal Dorjsuren(National Institutes of Health), Michael S. Toss(Nottingham City Hospital), Reem Ali(Hamad bin Khalifa University), Emad A. Rakha(Nottingham University Hospitals NHS Trust)
Cited by 24
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Hallmarks of neurodegenerative diseases
|Cell|2023|1.6k
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Workgroup Report: Public Health Strategies for Reducing Aflatoxin Exposure in Developing Countries
|Environmental Health Perspectives|2006|537